Drugs / Boostrix
Boostrix
Trials 31 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02543918 | Sep → Nov 2015 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05073003 | Oct 2021 → Jun 2025 | diarrheal disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05116241 | Nov 2021 → May 2024 | pertussis | ILiAD Biotechnologies | Completed | No outcome recorded |
| Phase 2 | NCT03589768 | Jan 2019 → Jul 2020 | Clostridium difficile colitis, diphtheria, pertussis, tetanus | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00505063 | Jul 2007 → Jun 2025 | childhood malignant neoplasm | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 316 trials | ||||||
| Phase 3 | NCT06798831 | Feb → Apr 2025 overdue | — | BioNet-Asia Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03311659 | Jan → Aug 2018 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01988857 | Feb → May 2014 | diphtheria, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT02052596 | Feb 2014 → Jun 2015 | herpes zoster | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01738477 | Jan 2013 → Apr 2014 | diphtheria, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01755689 | Jan 2013 → Apr 2014 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01767376 | Jan 2013 → Jan 2014 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00835237 | Feb → Jul 2009 | diphtheria, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00489970 | Jun 2007 → Sep 2011 | diphtheria, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00452686 | Mar → May 2007 | diphtheria, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00406562 | Jan → Feb 2007 | diphtheria, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00385255 | Oct 2006 → Feb 2007 | diphtheria, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00369824 | Sep 2006 → Nov 2007 | human papilloma virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00346073 | Jul 2006 → Mar 2007 | diphtheria, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01277705 | Jan → Apr 2002 | diphtheria, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01262924 | Oct 1997 → Dec 1998 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 410 trials | ||||||
| Phase 4 | NCT03909126 | Jun 2019 → May 2021 | pertussis | St. Justine's Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02377349 | Oct 2015 → Aug 2017 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT02072525 | Apr 2014 → Jun 2015 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT01424644 | Sep 2011 → Dec 2012 | meningococcal meningitis | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT01362322 | Jul 2011 → Sep 2012 | diphtheria, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT01147900 | Jun 2010 → May 2012 | diphtheria, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT00548171 | Nov 2007 → Apr 2008 | diphtheria, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT00282295 | Jan → Aug 2006 | diphtheria, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT00544271 | May 2003 → Jan 2004 | diphtheria, tetanus | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 4 | NCT01294605 | Apr 2003 → Sep 2004 | diphtheria, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
Also used as a comparator or background therapy in 18 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05613205 Comparator | Nov 2022 → Dec 2023 | typhoid fever | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT03035370 Background | Sep 2016 → Apr 2018 | pertussis | DBV Technologies | Completed | No outcome recorded |
| Phase 1 | NCT02382913 Comparator | Apr → Jun 2015 | pertussis | Novartis | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT06997627 Comparator | Jun 2025 → May 2026 overdue | — | GC Biopharma Corp | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02813486 Comparator | Jun → Nov 2016 | diphtheria, pertussis, tetanus | Green Cross Corporation | Unknown | No outcome recorded |
| Phase 1/2 | NCT02587520 Comparator | Oct 2015 → Feb 2017 | diphtheria, pertussis, tetanus | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT04238975 Comparator | Oct 2019 → Feb 2021 | diphtheria, pertussis, tetanus | Green Cross Corporation | Unknown | No outcome recorded |
| Phase 2 | NCT02946190 Comparator | Oct 2016 → Mar 2017 | pertussis | University Hospital, Geneva | Completed | No outcome recorded |
| Phase 2 | NCT02676895 Comparator | Aug 2016 → Mar 2017 | shigellosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT02753413 Comparator | Apr → Jun 2016 | respiratory syncytial virus infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT02360475 Comparator | Mar → Jul 2015 | respiratory syncytial virus infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02587221 Comparator | Sep 2016 → Jul 2018 | influenza | Seqirus | Completed | No outcome recorded |
| Phase 46 trials | ||||||
| Phase 4 | NCT02555540 Comparator | Aug → Dec 2015 | — | University Hospital, Ghent | Completed | No outcome recorded |
| Phase 4 | NCT02408926 Background | Apr 2015 → Aug 2018 | pertussis | University of Antwerp | Completed | No outcome recorded |
| Phase 4 | NCT02526394 Comparator | Sep 2013 → Mar 2017 | meningococcal meningitis, pertussis | Public Health England | Completed | No outcome recorded |
| Phase 4 | NCT01698346 Comparator | Feb 2012 → Dec 2015 | pertussis, pregnancy disorder | University of Antwerp | Completed | No outcome recorded |
| Phase 4 | NCT01301703 Comparator | Mar → Dec 2011 | rheumatoid arthritis | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT00319553 Comparator | May 2006 → Oct 2008 | diphtheria, pertussis, tetanus | Sanofi | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 52 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Boostrix | “Subjects, male or female, between, and including, 19 and 64 years of age received a single dose of Boostrix® vaccine administered intramuscularly in the deltoid region of the...” NCT00346073 ↗50“Two clinical studies were undertaken to evaluate the immunogenicity of an adult-type dTpa booster vaccine (Boostrix by GlaxoSmithKline Biologicals).” PMID 14670310 ↗ Jan 2004 “0.5 ml single dose of Tdap (Tetanus, Diphtheria, Acellular Pertussis Vaccine), BOOSTRIX administered intramuscularly to pregnant women” NCT03589768 ↗ “Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Previously Boosted Young Adults” NCT01738477 ↗ “Participants received TYPHIM VI as comparator intramuscularly on Day 1, and BOOSTRIX as comparator on Day 169.” NCT05613205 ↗ “Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine(Tdap) is Boostrix®.” NCT01424644 ↗ “Patients and controls will be vaccinated with BOOSTRIX (Tdap vaccine)” NCT01301703 ↗ “Healthy participants aged 10-18 years received Boostrix®.” NCT02587520 ↗ “Pertussis vaccine (Boostrix®, GSK Biologicals, Rixensart)” NCT01698346 ↗ “Tdap(BOOSTRIX), Hepatitis B #2” NCT00505063 ↗ “Boostrix + Meningitec” NCT02526394 ↗ “Boostrix” NCT06798831 ↗ |
| Known as | Boostrix dTpa | “Four weeks after the second Viaskin application (at Day 42 of the study), all subjects will receive a dose of diphtheria-tetanus-pertussis vaccine (Boostrix® dTpa) to ensure...” NCT03035370 ↗ |
| Known as | dTpa | “Reduced-antigen-content diphtheria-tetanus-acellular pertussis (dTpa) vaccine, Boostrix™, is indicated for booster vaccination of children, adolescents and adults.” PMID 26075317 ↗ 2015 |
| Known as | Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine | “Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine(Tdap) is Boostrix®.” NCT01424644 ↗ |
| Known as | Tdap | “We assessed co-administration of quadrivalent meningococcal serogroups A, C, W and Y tetanus toxoid-conjugate vaccine (MenACWY-TT), human papillomavirus 16/18 AS04-adjuvanted...” PMID 29789243 ↗ May 20181“Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine(Tdap) is Boostrix®.” NCT01424644 ↗ |
| Modality | Vaccine | “tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine” PMID 21134450 ↗ Dec 2010 |
| Route | Intramuscular | “The Boostrix® vaccine was administered intramuscularly” NCT00282295 ↗ |